These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The use of selective serotonin reuptake inhibitors in children and adolescents with major depression. Scahill L; Hamrin V; Pachler ME J Child Adolesc Psychiatr Nurs; 2005; 18(2):86-9. PubMed ID: 15966952 [TBL] [Abstract][Full Text] [Related]
44. Clinical implications of selective serotonin reuptake inhibitors-selective serotonin norepinephrine reuptake inhibitors pharmacogenetics during pregnancy and lactation. Koren G; Ornoy A Pharmacogenomics; 2018 Sep; 19(14):1139-1145. PubMed ID: 30105921 [TBL] [Abstract][Full Text] [Related]
45. May depressed and anxious patients with carcinoid syndrome benefit from treatment with selective serotonin reuptake inhibitors (SSRIs)?: findings from a case report. Nobels A; Geboes K; Lemmens GM Acta Oncol; 2016 Nov; 55(11):1370-1372. PubMed ID: 27169982 [No Abstract] [Full Text] [Related]
46. Therapeutic drug monitoring of escitalopram in an outpatient setting. Reis M; Chermá MD; Carlsson B; Bengtsson F; Ther Drug Monit; 2007 Dec; 29(6):758-66. PubMed ID: 18043473 [TBL] [Abstract][Full Text] [Related]
48. Exacerbation of panic disorder with rifampin therapy in a patient receiving citalopram. Kukoyi O; Argo TR; Carnahan RM Pharmacotherapy; 2005 Mar; 25(3):435-7. PubMed ID: 15843291 [TBL] [Abstract][Full Text] [Related]
49. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. Baumann P; Nil R; Souche A; Montaldi S; Baettig D; Lambert S; Uehlinger C; Kasas A; Amey M; Jonzier-Perey M J Clin Psychopharmacol; 1996 Aug; 16(4):307-14. PubMed ID: 8835706 [TBL] [Abstract][Full Text] [Related]
50. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. Harvey AT; Preskorn SH J Clin Psychopharmacol; 1996 Oct; 16(5):345-55. PubMed ID: 8889906 [TBL] [Abstract][Full Text] [Related]
54. Too soon to judge value of pharmacogenetic testing in selecting antidepressant. Thompson CA Am J Health Syst Pharm; 2007 Mar; 64(5):453. PubMed ID: 17322153 [No Abstract] [Full Text] [Related]
55. Interactive case conference. First episode: depression and panic disorder. Dunner DL CNS Spectr; 2005 Sep; 10(9):696-7. PubMed ID: 16142209 [No Abstract] [Full Text] [Related]
56. Meniere's disease: some patients benefit significantly from SSRIs. Overton M Aust Fam Physician; 2003; 32(1-2):8. PubMed ID: 12647651 [No Abstract] [Full Text] [Related]
57. Citalopram, a selective serotonin reuptake inhibitor, improves symptoms of Friedreich's ataxia. Rohr A; Eichler K; Hafezi-Moghadam N Pharmacopsychiatry; 1999 May; 32(3):113-4. PubMed ID: 10463380 [TBL] [Abstract][Full Text] [Related]
58. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Chen F; Larsen MB; Sánchez C; Wiborg O Eur Neuropsychopharmacol; 2005 Mar; 15(2):193-8. PubMed ID: 15695064 [TBL] [Abstract][Full Text] [Related]
59. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Tack J; Broekaert D; Fischler B; Van Oudenhove L; Gevers AM; Janssens J Gut; 2006 Aug; 55(8):1095-103. PubMed ID: 16401691 [TBL] [Abstract][Full Text] [Related]
60. Escitalopram-Induced Rash. Prabhakar D; Sablaban I Prim Care Companion CNS Disord; 2019 Jan; 21(1):. PubMed ID: 30806996 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]